
AgnÃ"s Fournier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1619480/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Statin Use and Skin Cancer Risk: A Prospective Cohort Study. Journal of Investigative Dermatology, 2022, 142, 1318-1325.e5.	0.7	4
2	Colorectal cancer risk following appendectomy: a pooled analysis of three large prospective cohort studies. Cancer Communications, 2022, 42, 486-489.	9.2	5
3	Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 643-652.	2.5	5
4	Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study. Breast Cancer Research, 2021, 23, 47.	5.0	3
5	Associations between smoking and blood-group, and the risk of dyslipidaemia amongst French women. Scientific Reports, 2021, 11, 14844.	3.3	2
6	Association between cardiovascular risk-factors and venous thromboembolism in a large longitudinal study of French women. Thrombosis Journal, 2021, 19, 58.	2.1	3
7	Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Medicine, 2021, 19, 186.	5.5	9
8	Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: A Prospective Study and Meta-Analysis. JNCI Cancer Spectrum, 2021, 5, pkab084.	2.9	8
9	Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort. Menopause, 2021, 28, 1204-1208.	2.0	10
10	Mediation analysis of the alcoholâ€postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. International Journal of Cancer, 2020, 146, 759-768.	5.1	14
11	Premenopausal Use of Progestogens and Cutaneous Melanoma Risk: A French Prospective Cohort Study. American Journal of Epidemiology, 2020, 189, 314-329.	3.4	2
12	Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2020, 146, 3267-3280.	5.1	14
13	Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Research, 2020, 22, 118.	5.0	13
14	Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1654-1664.	2.5	3
15	Increased risk of type 2 diabetes in antidepressant users: evidence from a 6â€year longitudinal study in the E3N cohort. Diabetic Medicine, 2020, 37, 1866-1873.	2.3	4
16	Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1746-1754.	2.5	8
17	Prospective analysis of circulating metabolites and breast cancer in EPIC. BMC Medicine, 2019, 17, 178.	5.5	79
18	Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study. International Journal of Cancer, 2019, 145, 1754-1767.	5.1	16

#	Article	IF	CITATIONS
19	Use of dietary supplements containing soy isoflavones and breast cancer risk among women aged >50Ây: a prospective study. American Journal of Clinical Nutrition, 2019, 109, 597-605.	4.7	17
20	Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1076-1085.	2.5	9
21	Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. BMC Medicine, 2019, 17, 221.	5.5	18
22	Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. Journal of Hepatology, 2019, 70, 885-892.	3.7	58
23	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. International Journal of Cancer, 2019, 145, 58-69.	5.1	28
24	Associations Between Migraine and Type 2 Diabetes in Women. JAMA Neurology, 2019, 76, 257.	9.0	39
25	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. American Journal of Epidemiology, 2019, 188, 274-281.	3.4	6
26	The impact of historical breastfeeding practices on the incidence of cancer in France in 2015. Cancer Causes and Control, 2018, 29, 325-332.	1.8	2
27	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	5.1	18
28	Multimorbidity medications and poor asthma prognosis. European Respiratory Journal, 2018, 51, 1702114.	6.7	17
29	Asthma Medication Ratio Phenotypes in Elderly Women. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 897-906.e5.	3.8	3
30	Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk. Cancer Research, 2018, 78, 302-308.	0.9	18
31	Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. International Journal of Cancer, 2018, 142, 1332-1342.	5.1	42
32	Risk of asthma onset after natural and surgical menopause: Results from the French E3N cohort. Maturitas, 2018, 118, 44-50.	2.4	12
33	Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. Breast Cancer Research, 2018, 20, 147.	5.0	24
34	Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer, 2018, 18, 1010.	2.6	9
35	Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study. International Journal of Cancer, 2018, 143, 2390-2399.	5.1	21
36	Use of benzodiazepines and cardiovascular mortality in a cohort of women aged over 50Âyears. European Journal of Clinical Pharmacology, 2018, 74, 1475-1484.	1.9	11

#	Article	IF	CITATIONS
37	Nonsteroidal antiâ€inflammatory drug use and breast cancer risk in a European prospective cohort study. International Journal of Cancer, 2018, 143, 1688-1695.	5.1	11
38	Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clinical Cancer Research, 2017, 23, 4181-4189.	7.0	26
39	Trajectories of Depressive Symptoms Before Diagnosis of Dementia. JAMA Psychiatry, 2017, 74, 712.	11.0	361
40	Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. International Journal of Cancer, 2017, 140, 1317-1323.	5.1	28
41	Long-Term Exposure to Ambient Air Pollution and Incidence of Postmenopausal Breast Cancer in 15 European Cohorts within the ESCAPE Project. Environmental Health Perspectives, 2017, 125, 107005.	6.0	104
42	Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. Journal of Clinical Oncology, 2017, 35, 3230-3239.	1.6	13
43	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS ONE, 2016, 11, e0147029.	2.5	102
44	Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Internal Medicine, 2016, 176, 816.	5.1	1,000
45	Vitamin C supplement intake and postmenopausal breast cancer risk: interaction with dietary vitamin C. American Journal of Clinical Nutrition, 2016, 104, 228-234.	4.7	18
46	Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort. International Journal of Cancer, 2016, 139, 2193-2200.	5.1	12
47	A treelet transform analysis to relate nutrient patterns to the risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutrition, 2016, 19, 242-254.	2.2	26
48	Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2015, 136, 399-410.	5.1	36
49	Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: The EPIC study. International Journal of Cancer, 2015, 136, 1218-1227.	5.1	69
50	Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). American Journal of Clinical Nutrition, 2015, 101, 613-621.	4.7	284
51	Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort. American Journal of Clinical Nutrition, 2015, 102, 966-973.	4.7	11
52	Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. British Journal of Cancer, 2015, 112, 162-166.	6.4	21
53	Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort. PLoS Medicine, 2014, 11, e1001660.	8.4	12
54	Health characteristics of women beginning postmenopausal hormone therapy. Menopause, 2014, 21, 687-693.	2.0	8

#	Article	lF	CITATIONS
55	Risks of Endometrial Cancer Associated With Different Hormone Replacement Therapies in the E3N Cohort, 1992-2008. American Journal of Epidemiology, 2014, 180, 508-517.	3.4	76
56	Recent Recreational Physical Activity and Breast Cancer Risk in Postmenopausal Women in the E3N Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1893-1902.	2.5	35
57	Physical activity, sex steroid, and growth factor concentrations in pre- and post-menopausal women: a cross-sectional study within the EPIC cohort. Cancer Causes and Control, 2014, 25, 111-124.	1.8	10
58	Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, 2014, 145, 535-543.	2.5	82
59	Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer, 2013, 13, 584.	2.6	74
60	Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. International Journal of Cancer, 2013, 132, 1667-1678.	5.1	72
61	Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. Cmaj, 2013, 185, 555-561.	2.0	34
62	Prospective Study on Physical Activity and Risk of In Situ Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2209-2219.	2.5	14
63	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Research, 2012, 14, R76.	5.0	94
64	Response to the letter by Acar. Pharmacoepidemiology and Drug Safety, 2012, 21, 1245-1246.	1.9	0
65	Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118â€^964 women with breast cancer from 117 epidemiological studies. Lancet Oncology, The, 2012, 13, 1141-1151.	10.7	753
66	Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiology and Drug Safety, 2012, 21, 343-351.	1.9	37
67	Response to the letter by Deltour et al Pharmacoepidemiology and Drug Safety, 2012, 21, 586-588.	1.9	1
68	Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias?. European Journal of Epidemiology, 2012, 27, 439-452.	5.7	22
69	Interactions Between Genetic Variants and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. Journal of the National Cancer Institute, 2011, 103, 1252-1263.	6.3	147
70	Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes and Control, 2011, 22, 1075-1084.	1.8	51
71	Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2011, 128, 144-156.	5.1	125
72	Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2011, 128, 1881-1889.	5.1	28

#	Article	IF	CITATIONS
73	Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 2011, 105, 1436-1442.	6.4	160
74	Risk of Osteoporotic Fractures After Discontinuation of Menopausal Hormone Therapy: Results From the E3N Cohort. American Journal of Epidemiology, 2011, 174, 12-21.	3.4	17
75	Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause, 2011, 18, 219-223.	2.0	21
76	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	5.1	68
77	Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 127, 442-451.	5.1	223
78	Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 2010, 103, 1755-1759.	6.4	46
79	Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 340-345.	2.4	233
80	Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition. American Journal of Epidemiology, 2010, 172, 1394-1403.	3.4	117
81	Postmenopausal hormone therapy and asthma onset in the E3N cohort. Thorax, 2010, 65, 292-297.	5.6	80
82	Should transdermal rather than oral estrogens be used in menopausal hormone therapy?: a review. Menopause International, 2010, 16, 23-32.	1.6	8
83	Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?. Journal of Clinical Oncology, 2009, 27, 5138-5143.	1.6	123
84	Physical Activity and Ovarian Cancer Risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 351-354.	2.5	70
85	Breast Cancer and Hormonal Therapy in Postmenopausal Women. New England Journal of Medicine, 2009, 360, 2366-2367.	27.0	6
86	Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N-EPIC Prospective Cohort Study. American Journal of Epidemiology, 2009, 170, 1257-1267.	3.4	171
87	Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia, 2009, 52, 2092-2100.	6.3	64
88	Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women. Climacteric, 2009, 12, 410-418.	2.4	6
89	Risk factors for onset of menopausal symptoms. Maturitas, 2008, 60, 108-121.	2.4	69
90	Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)? Revue D'Epidemiologie Et De Sante Publique, 2008, 56, e8-e12	0.5	1

#	Article	IF	CITATIONS
91	Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor–Defined Invasive Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1260-1268.	1.6	156
92	Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Carcinogenesis, 2008, 29, 1360-1366.	2.8	39
93	Progestagens Use Before Menopause and Breast Cancer Risk According to Histology and Hormone Receptors. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2723-2728.	2.5	19
94	Oral progestagens before menopause and breast cancer risk. British Journal of Cancer, 2007, 96, 841-844.	6.4	36
95	Dietary Lignan Intake and Postmenopausal Breast Cancer Risk by Estrogen and Progesterone Receptor Status. Journal of the National Cancer Institute, 2007, 99, 475-486.	6.3	166
96	Physical Activity and Breast Cancer Risk: The European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 36-42.	2.5	127
97	Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?. American Journal of Epidemiology, 2007, 166, 1451-1460.	3.4	4
98	Unsuspected Consequences of the Adolescent Overweight Epidemic. Pediatrics, 2007, 120, 924-925.	2.1	1
99	Personal History of Endometriosis and Risk of Cutaneous Melanoma in a Large Prospective Cohort of French Women. Archives of Internal Medicine, 2007, 167, 2061.	3.8	32
100	Risk of onset of menopausal symptoms in periods surrounding menopause. Maturitas, 2007, 58, 340-347.	2.4	4
101	EPIC-Heart: The cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. European Journal of Epidemiology, 2007, 22, 129-141.	5.7	91
102	Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, 2007, 107, 103-111.	2.5	532
103	Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes and Control, 2007, 18, 361-373.	1.8	104
104	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation Into Cancer and Nutrition (EPIC). Journal of Urology, 2006, 175, 250-250.	0.4	0
105	Breast Cancer Risk in Relation to Different Types of Hormone Replacement Therapy: Update of the E3N Results. American Journal of Epidemiology, 2006, 163, S161-S161.	3.4	0
106	Hormone Replacement Therapy and Osteoporotic Fractures. American Journal of Epidemiology, 2006, 163, S175-S175.	3.4	0
107	Breast cancer risk in relation to different types of hormone replacement therapy in the E3Nâ€EPIC cohort. International Journal of Cancer, 2005, 114, 448-454.	5.1	338
108	Breast cancer in HRT use. International Journal of Cancer, 2005, 116, 999-999.	5.1	1

#	Article	IF	CITATIONS
109	Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes and Control, 2005, 16, 537-544.	1.8	14
110	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 2005, 97, 755-765.	6.3	391
111	Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer, 2005, 12, 1071-1082.	3.1	435